Ad is loading...
AVTE
Price
$2.53
Change
-$0.03 (-1.17%)
Updated
Nov 15 closing price
One day until earnings call
OVID
Price
$1.06
Change
-$0.09 (-7.83%)
Updated
Nov 15 closing price
120 days until earnings call
Ad is loading...

AVTE vs OVID

Header iconAVTE vs OVID Comparison
Open Charts AVTE vs OVIDBanner chart's image
Aerovate Therapeutics
Price$2.53
Change-$0.03 (-1.17%)
Volume$524.25K
CapitalizationN/A
Ovid Therapeutics
Price$1.06
Change-$0.09 (-7.83%)
Volume$437.65K
CapitalizationN/A
AVTE vs OVID Comparison Chart
Loading...
AVTE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
OVID
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
AVTE vs. OVID commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVTE is a Sell and OVID is a StrongSell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (AVTE: $2.53 vs. OVID: $1.06)
Brand notoriety: AVTE and OVID are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AVTE: 54% vs. OVID: 271%
Market capitalization -- AVTE: $73.05M vs. OVID: $75.23M
AVTE [@Biotechnology] is valued at $73.05M. OVID’s [@Biotechnology] market capitalization is $75.23M. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVTE’s FA Score shows that 1 FA rating(s) are green whileOVID’s FA Score has 0 green FA rating(s).

  • AVTE’s FA Score: 1 green, 4 red.
  • OVID’s FA Score: 0 green, 5 red.
According to our system of comparison, AVTE is a better buy in the long-term than OVID.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AVTE’s TA Score shows that 3 TA indicator(s) are bullish while OVID’s TA Score has 3 bullish TA indicator(s).

  • AVTE’s TA Score: 3 bullish, 5 bearish.
  • OVID’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, AVTE is a better buy in the short-term than OVID.

Price Growth

AVTE (@Biotechnology) experienced а -6.99% price change this week, while OVID (@Biotechnology) price change was -18.46% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

AVTE is expected to report earnings on Mar 26, 2025.

OVID is expected to report earnings on Mar 17, 2025.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OVID($75.2M) and AVTE($73.1M) have the same market capitalization . OVID YTD gains are higher at: -67.081 vs. AVTE (-88.820). OVID has higher annual earnings (EBITDA): -66.55M vs. AVTE (-94.11M). AVTE has more cash in the bank: 104M vs. OVID (77M). AVTE has less debt than OVID: AVTE (681K) vs OVID (15.4M). OVID has higher revenues than AVTE: OVID (568K) vs AVTE (0).
AVTEOVIDAVTE / OVID
Capitalization73.1M75.2M97%
EBITDA-94.11M-66.55M141%
Gain YTD-88.820-67.081132%
P/E RatioN/AN/A-
Revenue0568K-
Total Cash104M77M135%
Total Debt681K15.4M4%
FUNDAMENTALS RATINGS
OVID: Fundamental Ratings
OVID
OUTLOOK RATING
1..100
35
VALUATION
overvalued / fair valued / undervalued
1..100
48
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
93
PRICE GROWTH RATING
1..100
88
P/E GROWTH RATING
1..100
94
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AVTEOVID
RSI
ODDS (%)
Bearish Trend 3 days ago
70%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
84%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
87%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
84%
Advances
ODDS (%)
Bullish Trend 17 days ago
84%
Bullish Trend 12 days ago
76%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
85%
View a ticker or compare two or three
Ad is loading...
AVTE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
OVID
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TBNK10.80-0.03
-0.28%
Territorial Bancorp
ERJ37.92-0.28
-0.73%
Embraer SA
NOW1011.39-28.41
-2.73%
SERVICENOW
ADTN7.75-0.22
-2.76%
ADTRAN Holdings
RXRX6.18-0.74
-10.64%
Recursion Pharmaceuticals

AVTE and

Correlation & Price change

A.I.dvisor indicates that over the last year, AVTE has been closely correlated with OVID. These tickers have moved in lockstep 90% of the time. This A.I.-generated data suggests there is a high statistical probability that if AVTE jumps, then OVID could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVTE
1D Price
Change %
AVTE100%
-1.17%
OVID - AVTE
90%
Closely correlated
-7.83%
NTLA - AVTE
46%
Loosely correlated
-7.61%
DNLI - AVTE
43%
Loosely correlated
-11.95%
BEAM - AVTE
41%
Loosely correlated
-8.59%
SNDX - AVTE
39%
Loosely correlated
-5.72%
More

OVID and

Correlation & Price change

A.I.dvisor indicates that over the last year, OVID has been closely correlated with AVTE. These tickers have moved in lockstep 90% of the time. This A.I.-generated data suggests there is a high statistical probability that if OVID jumps, then AVTE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OVID
1D Price
Change %
OVID100%
-7.83%
AVTE - OVID
90%
Closely correlated
-1.17%
NAUT - OVID
36%
Loosely correlated
-6.50%
TVTX - OVID
36%
Loosely correlated
-4.06%
NRIX - OVID
36%
Loosely correlated
-14.67%
ALEC - OVID
35%
Loosely correlated
-17.21%
More